An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Eli Lilly and Company4,299 enrolled

Overview

The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.

Study Type

OBSERVATIONAL

Enrollment

4,299

Conditions

Diabetes Mellitus, Type 2

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have been diagnosed with type 2 diabetes * Have presented within the normal course of care * Have been on their initial insulin therapy for ≥3 months (with or without any combination of approved non-insulin anti-diabetic medications) * Are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study * Have been fully informed and have given written consent for the use of their data * Have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires * Have not initiated basal bolus therapy (three mealtime insulin injections) Exclusion Criteria: * None

Locations (153)

Outcomes

Primary Outcomes

Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy

Multivariable logistic regression model examined baseline participant-, physician-, and healthcare system-related factors associated with the occurrence of any change in insulin therapy. Discrimination domain of the Interpersonal Processes of Care Survey \[IPC\] ranges from 1-5 with higher scores indicating more discrimination and Diabetes Distress Scale ranges from 1-6 with higher scores indicating more distress.

Time frame: Baseline through 24 months

Secondary Outcomes

Number of Hypoglycemic and Severe Hypoglycemic Episodes

Hypoglycemia and severe hypoglycemia episodes are self-reported by all participants with complete treatment data from one month prior to the baseline visit until the last visit (24 months). Patients were asked at each visit to self-report any hypoglycemia since their last visit. At the baseline visit participants were asked their hypoglycemia information for the month prior to the baseline visit.

Time frame: Baseline through 24 months

Number of Participants Adherent to Prescribed Insulin Therapy During the Study (Study Adherent)

MOSAIC participants answered the question: "How often did you miss your insulin shots during the last 7 days?". At each visit, participants were defined as visit adherent if the participant answered "I did not miss any shots" or "I missed some of my shots". They were defined as not visit adherent if he/she answered any of the following: "I missed about half of my shots", "I missed most of my shots", or "I missed all of my shots". A participant is defined to be study adherent if at least: 4 out of 5 visit adherent.

Time frame: Baseline through 24 months

Number of Participants Who Achieved Their Personalized HbA1c Target by the End of the Study

As diabetes management practices vary across the countries represented in MOSAIC, a more apt measure of reaching goal is the personalized target that was set for each patient at the beginning of the study.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Little Rock, Arkansas, United States

Orlando, Florida, United States

Wellington, Florida, United States

Canton, Georgia, United States

Crystal Lake, Illinois, United States

North Platte, Nebraska, United States

Reno, Nevada, United States

Burlington, North Carolina, United States

Greensboro, North Carolina, United States

Morganton, North Carolina, United States

...and 143 more locations